bluebird bio: How to play LEAPS options for growth and income

Key Pointsbluebird bio is a major beneficiary of gene therapy headlines as it has 3 FDA approval therapies.bluebird was a $158 stock in 2019, which has fallen as low as 87 cents in 2024.OTM LEAPS calls can be held while selling OTM front-month calls for income.5 stocks we like better than bluebird bioGene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT from CRISPR Therapeutics AG NASDAQ: CRSP and part ...